Mustang Bio (NASDAQ: MBIO) reported Q2 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).Financial Results:As of June ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Earnings Management Comments

Mustang Bio (MBIO) Secures $9.28M Grant to Fund Ongoing Phase 1 Clinical Trial of MB-103 (HER2-Specific CAR T Cells)August 13, 2019 8:04 AM Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate HighlightsAugust 9, 2019 4:06 PM Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate HighlightsAugust 9, 2019 4:05 PM